Learn from these experts amongst others:

Independent Best Practice Big Pharma: Innovative Business Development and Licensing Strategies

Almost every day we hear of announcements on new collaborations, agreements and indeed licensing deals – the pharmaceutical industry has become increasingly dynamic in finding the perfect match.

This is no surprise: To help reduce the impact of the impending 2011 patent cliff, Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures. Bear in mind that by 2014 Big Pharma will see over $63 billion of annual income washed away due to patent cliff.

To avoid portfolio or pipeline standstill licensing strategies have proven to be essential. In fact, an increasing proportion of revenue is expected to be generated from licensed products. Thus, the to-do-list is long: Evaluating drivers and resistors of licensing deals, building proper relationships with small pharma, biotech companies and academia, implementing a global business development concept. Learn at our international conference from experts about the numerous facets of licensing.

The conference includes cutting-edge case studies from Big Pharma and analyses the future potential of pharmaceutical licensing.

Establish new business opportunities and:

  • Stay competitive and identify major licensing strategies
  • Discuss pros and cons of in-licensing and out-licensing
  • Improve your business development strategies and create a company that is ready for Big Pharma’s future
Media Partners
_media

[ Register Now ]